News Article | February 27, 2017
— In this report, chloroform market value is provided for 2016 in USD millions along with an expected CAGR % as well as USD million value of CAS 67-66-3 industry in 2022. Regionally, the globe is segmented into North America, Europe, Japan, China, India and Southeast Asia to study their market size and regional analysis. 3 end user applications of chloroform market covering solvents & reagents, anesthetic and criminal use are studied in this research. Share of chloroform market is covered by applications as well supported with potential applications in the future. This comprehensive research offers insights into how chloroform market gained its standing, globally. Reliable, verified and cross-referenced (wherever feasible) data help understand the Chloroform industry analysis in a better way to take business decisions. Add to this secondary research, primary interviews with selected participants (spread across - but not all inclusive for each report - executives at C-level, analysts and experts of niche markets + trends + trade, consultants, etc of Chloroform market add professional and in-depth market research value to this study. The “Global Chloroform (CAS 67-66-3) Market Research Report 2017” is spread across 100 pages, supported with 125 data tables, charts and figures is now available with eMarketOrg.com at http://emarketorg.com/pro/global-chloroform-cas-67-66-3-market-research-report-2017/ . The team working on this report also ensured covering a bird's view for readers taking into account details that help identify and understand technology strengths, opportunities, weaknesses, and threats of the Chloroform market. Factors (vary from report to report) including classifications, applications, production information, technical data on revenue and analysis of consumption, revenue, supply, import-export and much more are covered as a part of this overview. These numbers when brought together with insights on leading companies and manufacturers active in Chloroform market for their products, company profiles, business and contact information make this research a one-of-its-kind read. With status of the market covered, this report then moves towards sharing forecasts for next few year covering development trends and analysis of Chloroform. The conclusion of the research aims to close the Chloroform market study with an objective to help its readers take concrete business decisions. Companies like Tokuyama Group, Productos Aditivos, BASF, Solvay, Dow Chemical Company, Arihant Chemicals, Ineos, Shin-Etsu Chemical and Akzonobel are profiled in this study. Get your questions on this report answered, before taking a purchase decision, via http://emarketorg.com/inquire-before-buying/?product-id=86710 . A partial list of data tables and figures provided for chloroform market in this research include: Table Raw Materials Sources of Chloroform (CAS 67-66-3) Major Manufacturers in 2016 Table Major Buyers of Chloroform (CAS 67-66-3) Table Distributors/Traders List Figure Global Chloroform Market (CAS 67-66-3) Capacity, Production and Growth Rate Forecast (2017-2022) Figure Global Chloroform (CAS 67-66-3) Revenue and Growth Rate Forecast (2017-2022) Figure Global Chloroform (CAS 67-66-3) Price and Trend Forecast (2017-2022) Table Global Chloroform (CAS 67-66-3) Production Forecast by Region (2017-2022) Figure Global Chloroform (CAS 67-66-3) Production Market Share Forecast by Region (2017-2022) Table Global Chloroform Market (CAS 67-66-3) Consumption Forecast by Region (2017-2022) Figure Global Chloroform (CAS 67-66-3) Consumption Market Share Forecast by Region (2017-2022) Table Global Chloroform (CAS 67-66-3) Production Forecast by Type (2017-2022) Figure Global Chloroform (CAS 67-66-3) Production Forecast by Type (2017-2022) Table Global Chloroform Market (CAS 67-66-3) Revenue Forecast by Type (2017-2022) Figure Global Chloroform (CAS 67-66-3) Revenue Market Share Forecast by Type (2017-2022) Table Global Chloroform (CAS 67-66-3) Price Forecast by Type (2017-2022) Table Global Chloroform (CAS 67-66-3) Consumption Forecast by Application (2017-2022) Figure Global Chloroform (CAS 67-66-3) Consumption Forecast by Application (2017-2022) Table Research Programs/Design for This Report Figure Bottom-up and Top-down Approaches for This Report Figure Data Triangulation Table Key Data Information from Secondary Sources Table Key Data Information from Primary Source Explore more reports on materials and chemicals markets at http://emarketorg.com/cat/materials-and-chemicals/page/3/ . About Us: eMarketOrg.com aims to provide businesses and organizations market intelligence products and services that help in making smart, instant and crucial decisions. Our database offers access to insights from industry leaders, experts and influencers on global and regional sectors, market trends, user behaviour, for companies as well as products. With data and information from reputable and trusted private and public sources, our clients are never short of statistics and analysis that are up to date. Connect With Us: Market Research Blog: http://emarketorg.com/blog/ News on current market trends and more: http://emarketorg.com/news1/ Follow Us on Twitter: https://twitter.com/emarketorg Follow us on G+ https://plus.google.com/collection/w7ioaB For more information, please visit http://emarketorg.com/pro/global-chloroform-cas-67-66-3-market-research-report-2017/
News Article | February 21, 2017
WATERTOWN, Mass.--(BUSINESS WIRE)--FORMA Therapeutics, a clinical-stage and fully integrated discovery and development company, announced today it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (“MJFF”) to further develop FORMA’s discovery program in protein homeostasis and ubiquitination for the treatment of Parkinson’s disease (PD). FORMA has established a research alliance with Professors Michael Clague and Sylvie Urbé from University of Liverpool, UK, and Dr. David Komander from Medical Research Council, Laboratory of Molecular Biology, Cambridge, UK, who will work alongside FORMA’s lead investigator, Dr. Stephanos Ioannidis, to advance the research plan subject to this prestigious award. Protein homeostasis and mitochondrial function are areas of biology that harbor promising new therapeutic targets for the treatment of PD. Recent research suggests that members of the deubiquitinase (DUB) family of proteins, which are critical in protein homeostasis, are also key modulators of mitophagy or mitochondrial clearance. The elimination of abnormal mitochondria by targeting DUB activity may be a route to intervene in the pathogenesis of PD. The grant from MJFF supports the advanced discovery and development of preclinical compounds targeting DUBs potentially relevant to PD. Shalini Padmanabhan, Ph.D., Associate Director of Research Programs at MJFF, said, “While accumulating evidence implicate defective mitochondria in PD pathology, exactly how DUBs regulate mitophagy is unclear. We hope this award will enable FORMA and its neurodegenerative disease alliance with leading investigators to understand the role of DUBs in clearance of damaged mitochondria and potentially lead to a promising treatment approach for PD patients.” “We are honored to receive recognition from MJFF for our research in protein homeostasis and to collaborate with its network in PD. This award provides support to further enable innovative research with our talented collaborators in the UK,” said John Hohneker, M.D., EVP and Head of Research and Development at FORMA. “We hope to gain a deeper understanding of the role of DUBs in PD that will ultimately facilitate the advancement of new therapies for patients.” As the world’s largest nonprofit funder of Parkinson’s research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $650 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. FORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology, inflammation & immunity, and other serious diseases. The Company’s fully integrated R&D team drives discovery and early clinical development of therapeutics for qualified targets in the areas of epigenetics, protein homeostasis and metabolism. Leveraging a world class network of academic investigators, clinical experts and partners, FORMA combines deep biology insight, chemistry expertise and early clinical development capabilities, to create drug candidates that will ultimately provide profound patient benefit. FORMA is headquartered in Watertown, MA near the epicenter of the Cambridge Life Sciences cluster, with additional chemistry operations in Branford, CT. www.formatherapeutics.com
News Article | September 1, 2016
Abstract: Kaho Maeda, Dr. Hideto Ito, Professor Kenichiro Itami of the JST-ERATO Itami Molecular Nanocarbon Project and the Institute of Transformative Bio-Molecules (ITbM) of Nagoya University, and their colleagues have reported in the Journal of the American Chemical Society, on the development of a new and simple strategy, "helix-to-tube" to synthesize covalent organic nanotubes. Organic nanotubes (ONTs) are organic molecules with tubular nanostructures. Nanostructures are structures that range between 1 nm and 100 nm, and ONTs have a nanometer-sized cavity. Various applications of ONTs have been reported, including molecular recognition materials, transmembrane ion channel/sensors, electro-conductive materials, and organic photovoltaics. Most ONTs are constructed by a self-assembly process based on weak non-covalent interactions such as hydrogen bonding, hydrophobic interactions and π-π interactions between aromatic rings. Due to these relatively weak interactions, most non-covalent ONTs possess a relatively fragile structure. Covalent ONTs, whose tubular skeletons are cross-linked by covalent bonding (a bond made by sharing of electrons between atoms) could be synthesized from non-covalent ONTs. While covalent ONTs show higher stability and mechanical strength than non-covalent ONTs, the general synthetic strategy for covalent ONTs was yet to be established. A team led by Hideto Ito and Kenichiro Itami has succeeded in developing a simple and effective method for the synthesis of robust covalent ONTs (tube) by an operationally simple light irradiation of a readily accessible helical polymer (helix). This so-called "helix-to-tube" strategy is based on the following steps: 1) polymerization of a small molecule (monomer) to make a helical polymer followed by, 2) light-induced cross-linking at longitudinally repeating pitches across the whole helix to form covalent nanotubes. With their strategy, the team designed and synthesized diacetylene-based helical polymers (acetylenes are molecules that contain carbon-carbon triple bonds), poly(m-phenylene diethynylene)s (poly-PDEs), which has chiral amide side chains that are able to induce a helical folding through hydrogen-bonding interactions. The researchers revealed that light-induced cross-linking at longitudinally aligned 1,3-butadiyne moieties (a group of molecules that contain four carbons with triple bonds at the first and third carbons) could generate the desired covalent ONT. "This is the first time in the world to show that the photochemical polymerization reaction of diynes is applicable to the cross-linking reaction of a helical polymer," says Maeda, a graduate student who mainly conducted the experiments. The "helix-to-tube" method is expected to be able to generate a range of ONT-based materials by simply changing the arene (aromatic ring) unit in the monomer. "One of the most difficult parts of this research was how to obtain scientific evidence on the structures of poly-PDEs and covalent ONTs," says Ito, one of the leaders of this study. "We had little experience with the analysis of polymers and macromolecules such as ONTs. Fortunately, thanks to the support of our collaborators in Nagoya University, who are specialists in these particular research fields, we finally succeeded in characterizing these macromolecules by various techniques including spectroscopy, X-ray diffraction, and microscopy." "Although it took us about a year to synthesize the covalent ONT, it took another one and a half year to determine the structure of the nanotube," says Maeda. "I was extremely excited when I first saw the transmission electron microscopy (TEM) images, which indicated that we had actually made the covalent ONT that we were expecting," she continues. "The best part of the research for me was finding that the photochemical cross-linking had taken place on the helix for the first time," says Maeda. "In addition, photochemical cross-linking is known to usually occur in the solid phase, but we were able to show that the reaction takes place in the solution phase as well. As the reactions have never been carried out before, I was dubious at first, but it was a wonderful feeling to succeed in making the reaction work for the first time in the world. I can say for sure that this was a moment where I really found research interesting." "We were really excited to develop this simple yet powerful method to achieve the synthesis of covalent ONTs," says Itami, the director of the JST-ERATO project and the center director of ITbM. "The "helix-to-tube" method enables molecular level design and will lead to the synthesis of various covalent ONTs with fixed diameters and tube lengths with desirable functionalities." "We envisage that ongoing advances in the "helix-to-tube" method may lead to the development of various ONT-based materials including electro-conductive materials and luminescent materials," says Ito. "We are currently carrying out work on the "helix-to-tube" methodology and we hope to synthesize covalent ONTs with interesting properties for various applications." About Nagoya University JST-ERATO Itami Molecular Nanocarbon Project The JST-ERATO Itami Molecular Nanocarbon Project was launched at Nagoya University in April 2014. This is a 5-year project that seeks to open the new field of nanocarbon science. This project entails the design and synthesis of as-yet largely unexplored nanocarbons as structurally well-defined molecules, and the development of novel, highly functional materials based on these nanocarbons. Researchers combine chemical and physical methods to achieve the controlled synthesis of well-defined uniquely structured nanocarbon materials, and conduct interdisciplinary research encompassing the control of molecular arrangement and orientation, structural and functional analysis, and applications in devices and biology. The goal of this project is to design, synthesize, utilize, and understand nanocarbons as molecules. About WPI-ITbM The Institute of Transformative Bio-Molecules (ITbM) at Nagoya University in Japan is committed to advance the integration of synthetic chemistry, plant/animal biology and theoretical science, all of which are traditionally strong fields in the university. ITbM is one of the research centers of the Japanese MEXT (Ministry of Education, Culture, Sports, Science and Technology) program, the World Premier International Research Center Initiative (WPI). The aim of ITbM is to develop transformative bio-molecules, innovative functional molecules capable of bringing about fundamental change to biological science and technology. Research at ITbM is carried out in a "Mix-Lab" style, where international young researchers from various fields work together side-by-side in the same lab, enabling interdisciplinary interaction. Through these endeavors, ITbM will create "transformative bio-molecules" that will dramatically change the way of research in chemistry, biology and other related fields to solve urgent problems, such as environmental issues, food production and medical technology that have a significant impact on the society. About JST-ERATO ERATO (The Exploratory Research for Advanced Technology), one of the Strategic Basic Research Programs, aims to form a headstream of science and technology, and ultimately contribute to science, technology, and innovation that will change society and the economy in the future. In ERATO, a Research Director, a principal investigator of ERATO research project, establishes a new research base in Japan and recruits young researchers to implement his or her challenging research project within a limited time frame. For more information, please click If you have a comment, please us. Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
News Article | March 18, 2016
Abstract: By studying an unusual group of magnetic microorganisms, scientists at UC Berkeley have uncovered a new and unexpected function for a ubiquitous protein family. Proteases are workhorse enzymes found in all living organisms that act in general cellular maintenance and communication by chewing up proteins. In a paper publishing in the Open Access journal PLOS Biology on March 16th 2016, the Komeili lab, along with collaborators in the Hurley and Chang groups, have now shown that a bacterial protein called MamO has been transformed from a common protease to an inactive enzyme that helps to build magnetic nanoparticles using a novel metal-binding motif. Many organisms, ranging from mammals to small single-celled algae, add functionality to their cells through the construction of elaborate three-dimensional minerals. The products of these "biomineralization" processes are of great interest in both basic and industrial settings. "We would like to know how minerals are built in nature since they constitute a fundamental survival strategy for many organisms," said Dr. Komeili. In addition, scientists are interested in mimicking natural biomineralization systems to design customized nanoparticles for use in a number of applications. In order to study the biological control of mineral production, Komeili and his team have been studying how a group of microorganisms, called magnetotactic bacteria, makes chains of magnetic crystals that allow the cells to swim along the earth's geomagnetic field. Their study focuses on Magnetospirillum magneticum AMB-1, a bacterium that builds small compartments called magnetosomes, which house the machinery for crystallizing iron atoms to make magnetite. Komeili's group knew that two proteins, MamE and MamO, are required at the earliest stages of mineral formation in AMB-1. Based on predicted similarities to known enzymes in the DNA sequences for each gene, both proteins had been designated as proteases. In an effort to understand details about how the protein works, David Hershey, a graduate student in the Komeili lab, wanted to understand the precise architecture and activity of MamO. They used X-ray crystallography to define the atomic structure of MamO. At first glance, MamO adopts a shape that is quite similar to that of other proteases. But by examining the structure more closely, Hershey and his colleagues found that MamO is riddled with changes that show it has lost the ability to perform its protease function. Instead, they discovered that MamO has an unexpected metal-binding activity that is required for AMB-1 to make magnetic crystals. Their results show that this ancient protease scaffold has been transformed into a novel metal-binding feature. Surprisingly, they found that a process similar to the one discovered in AMB-1 has occurred in all major groups of magnetotactic bacteria. Using the motifs they identified in MamO, they show that the genomes of these very diverse species also have inactive proteases. By tracing their evolutionary trajectory they found that the inactive proteases have arisen numerous times throughout the evolution of magnetosomes by convergent evolution. "We really thought that something this unusual would have evolved only once. That just isn't the case. It really just cements how unusual this process is," says David Hershey. Komeili and his team think that dramatic changes to the environment in the distant past provided the selective pressure that necessitated the presence of inactive proteases for formation of magnetic nanoparticles. The unexpected findings on the structure, activity and evolution of MamO has set the stage for a whole host of future explorations of biomineralization. Komeili's group wants to continue to investigate the precise role of metal-binding by MamO in biomineralization. Does MamO directly sequester iron to build the nucleus of the magnetic crystals? Or, does it act as a monitoring system for the local magnetosome environment, initiating biomineralization at the appropriate time? More broadly, Dr. Komeili hopes that the metal-binding activity of MamO can be exploited to produce magnetic particles synthetically using a simplified chemical system. Funding: DMH and AK are supported by grants from the National Institutes of Health R01GM084122 and the Office of Naval Research N000141310421. Beamline 8.3.1 at the Advanced Light Source, LBNL, is supported by the UC Office of the President, Multicampus Research Programs and Initiatives grant MR?15?328599 and the Program for Breakthrough Biomedical Research, which is partially funded by the Sandler Foundation. The Advanced Light Source is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy under Contract No. DE-AC02-05CH11231. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: The authors have declared that no competing interests exist. For more information, please click If you have a comment, please us. Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Baptista M.A.S.,Research Programs |
Dave K.D.,Research Programs |
Frasier M.A.,Research Programs |
Sherer T.B.,Research Programs |
And 8 more authors.
PLoS ONE | Year: 2013
The objective of this study was to evaluate the pathology time course of the LRRK2 knockout rat model of Parkinson's disease at 1-, 2-, 4-, 8-, 12-, and 16-months of age. The evaluation consisted of histopathology and ultrastructure examination of selected organs, including the kidneys, lungs, spleen, heart, and liver, as well as hematology, serum, and urine analysis. The LRRK2 knockout rat, starting at 2-months of age, displayed abnormal kidney staining patterns and/or morphologic changes that were associated with higher serum phosphorous, creatinine, cholesterol, and sorbitol dehydrogenase, and lower serum sodium and chloride compared to the LRRK2 wild-type rat. Urinalysis indicated pronounced changes in LRRK2 knockout rats in urine specific gravity, total volume, urine potassium, creatinine, sodium, and chloride that started as early as 1- to 2-months of age. Electron microscopy of 16-month old LRRK2 knockout rats displayed an abnormal kidney, lung, and liver phenotype. In contrast, there were equivocal or no differences in the heart and spleen of LRRK2 wild-type and knockout rats. These findings partially replicate data from a recent study in 4-month old LRRK2 knockout rats  and expand the analysis to demonstrate that the renal and possibly lung and liver abnormalities progress with age. The characterization of LRRK2 knockout rats may prove to be extremely valuable in understanding potential safety liabilities of LRRK2 kinase inhibitor therapeutics for treating Parkinson's disease.
News Article | February 15, 2017
Photosynthesis, creating oxygen and carbohydrates such as glucose from solar energy, water, and CO2, is indispensable for many species on this planet. However, it is unclear exactly how or when organisms evolved the ability to photosynthesize. These questions have fascinated scientists for a long time. A Japanese research group led by Associate Professor ASHIDA Hiroki (Graduate School of Human Development and Environment, Kobe University), Academic Researcher KONO Takunari (Graduate School of Human Development and Environment, Kobe University), and Professor MATSUMURA Hiroyoshi (Ritsumeikan University) has discovered an evolutionary model for the biological function that creates CO2 from glucose in photosynthesis. They found the mechanism in a primitive, non-photosynthesizing microbe. The research group discovered that Methanospirillum hungatei, a microbe (methanogenic archaeon) which is thought to have existed since before the development of photosynthesis, possess genes similar to those that play a role in photosynthesis. Through analysis of the enzymes synthesized by these genes and by investigating the metabolic substances within the organism, carrying out metabolome analysis to locate the trapped CO2, the team proved that Methanospirillum hungatei uses a primitive pathway that closely resembles the metabolic pathway used in photosynthesis to synthesize carbohydrates such as glucose. By clarifying part of the primitive metabolic pathway for photosynthesis, these findings could help to reveal how the photosynthesis system formed during evolution, a mystery that scientists have so far been unable to solve. If further light can be shed on the evolution of photosynthesis, scientists could potentially utilize this information to use and improve upon photosynthetic functions in order to increase production of crops and biofuel. This research was carried out as part of the Japan Science and Technology Agency (JST) Strategic Basic Research Programs. It was a joint project by Kobe University, Ritsumeikan University, the Nara Institute of Science and Technology, Birla Institute of Technology and Science (India), Osaka University and Shizuoka University. The findings were published on January 13 in the online journal Nature Communications. Please click here for further details: http://www.kobe-u.ac.jp/documents/en/NEWS/research/2017_01_31_01-01.pdf
News Article | February 15, 2017
The Conference Forum has announced the launch of the 2nd annual Clinical Trial Collaborations (CTC) conference in Boston on April 3-4, 2017. Led by Co-Chair Katherine Vandebelt, Global Head of Clinical Innovation at Eli Lilly, the CTC conference is the only strategic-level event in the US entirely focused on collaborations needed for 21st century drug development. Valerie Bowling, Executive Director of the CTC event, said, “The future of collaborations in drug development will require partners we never thought of before and new models for outstanding project delivery.” The CTC conference offers a variety of sessions that illustrate new collaboration techniques to drive improved clinical trial outcomes and bring clinical trial professionals closer to patients. Ken Getz, Director of Sponsored Research Programs at Tufts CSDD, will kick off the event with a presentation titled, “How the Clinical Collaborations Landscape Is Changing and Its Impact on R&D Operations.” The CTC conference also will feature three first-time keynote presentations: Takeda on their Transformational Clinical Development and Marketed Product Partnership with PRA Health Sciences with Dr Andy Plump, Director, Chief Medical and Scientific Officer, Takeda Models for Exquisite Project Delivery with Internal and External Partners with Dr Andy Lee, Senior Vice President, Head of Global Clinical Trial Operations, Merck In addition, the CTC conference will feature: The CTC conference offers presentations that deliver insightful clinical trial ideas and challenges for R&D operations, contract resource organizations (CROs) and site executives. It serves as an ideal event for senior-level clinical operation executives from large, medium and small pharmas, CROs, sites and patient advocacy organizations. The CTC event is proud to have CenterWatch as its exclusive lead media partner. CenterWatch is the leading source of clinical trial information for both clinical research professionals and patients. Learn more about CenterWatch. To find more about the CTC conference, click here. About The Conference Forum The Conference Forum is a drug development industry research firm and presents specialized events for professionals in the life science and healthcare industries. The company currently offer conferences for R&D leaders, clinical development professionals, biotech executives, VCs, drug delivery specialists, patient advocates and FDA executives. The Conference Forum’s mission is to create the best content, exchange ideas and provide quality networking to help move therapeutics to patients faster. Learn more about The Conference Forum.
News Article | December 5, 2016
YEMASSEE, S.C.--(BUSINESS WIRE)--Primate Breeding and Research Organization Alpha Genesis, Inc. (AGI) plans to spend $2 million to expand facilities at its Yemassee, South Carolina headquarters and will add up to 30 new jobs by the end of next year, Company officials said today. “Our 2016 pace of new business growth was extremely strong, and our 2017 outlook is very positive. As a result, we have made it an organizational priority to further enhance our facilities and technical staff to more efficiently meet the growing needs of our customers,” according to a statement from the Executive Offices of the Company. The Company indicates it will renovate more than 50,000 square feet of space “with state-of-the-art design and housing materials to ensure the highest possible standards of animal welfare. Once that phase is complete, we will be renovating our clinical care and research facilities, which play an integral role in all phases of our operations.” AGI Officials further stated that the company expects to increase its staff by 25 percent before the end of next year, to include 30 new jobs, based on the company's current roster of 120 employees. “Customers need superior services and require that more complex tasks be completed in faster time frames. These upgrades and the new talent we'll be bringing in will allow us to better meet these demands,” according to Dr. Greg Westergaard, AGI President and CEO. In the spring of 2016, the company opened new clinical health care facilities, a $1,000,000 investment that features improved housing, diagnostic, and treatment equipment which provide for superior care and immediate access to important measures of animal health and well-being. “The Animal Care and Research Programs at Alpha Genesis, Inc. contribute significantly to advancing scientific knowledge and to saving, improving and prolonging the lives of humans and animals. The Programs do so while upholding the highest standards of regulatory compliance and of humane and responsible treatment of nonhuman primates,” according to a statement from the Executive Offices of the Company. Animals are used in research only when no alternatives exist, AGI officials said. The potential benefits of primate research include an improved understanding of cancer, infectious diseases, neurological disorders, spinal cord injuries, basic biological and behavioral processes, and the development of new medicines, vaccines, devices and other treatments, according to scientific researchers. A recent USDA Inspection at AGI facilities found no non-compliant items which, according to Dr. Westergaard, “Speaks volumes in support of the excellent Animal Care provided to the primates at Alpha Genesis facilities, and is testament to the dedication and strong work ethic of the staff who do this important and challenging work.”
News Article | February 20, 2017
A National Institute for Materials Science (NIMS) research team led by senior researcher Nobuyuki Ishida and postdoctoral researcher Hideki Masuda, Surface Characterization Group, Research Center for Advanced Measurement and Characterization (Ishida is also a GREEN leader in the Nano Interface Characterization Group), succeeded in visualizing the nanoscale change in potential distribution in composite cathode materials of solid state lithium ion batteries (SS-LIBs) before and after charging/discharging the batteries. The results from this study may contribute to identifying the cause of high resistivity at the electrode–electrolyte interfaces, which has been hindering the development of high power density SS-LIBs. Due to their proven safety and excellent cycle characteristics, SS-LIBs are envisioned as promising next-generation storage batteries. However, because of the higher transfer resistance of lithium ions at the electrode–solid electrolyte interfaces compared to that at the electrode–liquid electrolyte interfaces, it is difficult to increase the power density of SS-LIBs. To understand the origin of interfacial resistivity, modeling was applied to the lithium ion depleted layer (space-charge layer), which forms in solid electrolytes when SS-LIBs are being charged, and to defects at the interfacial layer. To test these hypotheses, it is critical to measure the change in thickness of the space-charge layer, and the change in the distribution of lithium ion concentrations in that layer before and after charging/discharging the batteries. Then, it will be feasible to analyze the correlation between these measurements and interfacial resistivity. However, it had been difficult to measure electrical potential distribution in SS-LIB samples as the samples need to be extracted without compromising the performance of the battery. This had been a major issue preventing researchers from investigating the cause of interfacial resistivity. The research team developed a method whereby samples to be measured are cut out from SS-LIBs, the cross-section of the samples is treated, and potential distribution is measured using a scanning probe microscope, all of which are performed under an inert gas atmosphere or in vacuum. Then the team successfully visualized change in potential distribution arising from battery charging/discharging in the composite cathode at the high spatial resolution (≤50 nm) while keeping the battery performance. When SS-LIBs (provided by Taiyo Yuden Co., Ltd.) were evaluated using this method, the results indicated that the area where lithium ion concentrations decreased in the order of micrometers expanded in the solid electrolyte region, and that charging states were locally inhomogeneous. This method is applicable to the evaluation of space-charge layers in many types of SS-LIBs, and may contribute to understanding the causes of high interfacial resistivity in SS-LIBs. In addition, this method is also applicable to the evaluation of differences in charging/discharging states for individual active material particles that arise due to non-uniform electrical conductivity distribution in the composite electrode materials. Therefore, the new method may not only contribute to the design of interfaces to improve the performance of SS-LIBs but also apply to various battery analysis techniques including the analysis of causes of battery degradation. A part of this study was conducted in conjunction with the project titled "Formation of super-ion conduction path in all-solid-state lithium ion rechargeable battery through design of the crystal phase-interface with hierarchically controlled structures" (Katsuya Teshima, research director), which was carried out to supplement the project "Creation of innovative functional materials with advanced properties by hyper-nano-space design" (Tohru Setoyama, research supervisor), under the Strategic Basic Research Programs (specifically the CREST program) sponsored by the Japan Science and Technology Agency (JST). Explore further: Researchers find ultra-thin solution to primary obstacle in solid-state battery development More information: Hideki Masuda et al. Internal potential mapping of charged solid-state-lithium ion batteries using in situ Kelvin probe force microscopy, Nanoscale (2017). DOI: 10.1039/C6NR07971G
Centinel Spine, West Chester, Pa., has developed Ti-Active titanium plasma spray coatings on polyetheretherketone implants. The coating enhances the PEEK implants by providing an integrated microporous titanium surface designed to increase the coefficient of friction for enhanced insertion stability. The coating also enables cellular attachment and proliferation to maximize opportunities for fusion. Retrospective studies show clinically favorable outcomes for hip stems with plasma spray titanium coatings that result in excellent bony on-growth and long-term stability. Recent literature shows that 100% titanium interbody cages have more cellular attachment and proliferation properties than traditional PEEK cages. However, all-titanium cages have a higher modulus of elasticity and an increased risk of subsidence. Built on over 15 years of science and experience, Centinel Spine engineered the Ti-Active technology to merge the translucent and biomechanical advantages of PEEK with the hydrophilic and cell-friendly properties of titanium. Ti-Active devices are 20 times rougher than uncoated PEEK devices, and the 3D topography increases the surface area in contact with the bony endplates, maximizing the potential for fusion. "When titanium is added to the PEEK implant it makes the implant easier for cells to adhere and proliferate," says Celeste Abjornson, Ph.D., project coordinator with the Integrated Spine Research Programs at Hospital for Special Surgery in New York City. These scientists recently published a paper examining the different roughness profiles of titanium coatings. They reported that when the titanium coating achieves the right roughness, the cells are able to express different growth factors and proteins.